JF
EGRX

Jump Financial’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jump Financial’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,734
Closed -$40K – 2098
2024
Q3 		$40K Sell
10,734
-1,456
-12% -$6.95K ﹤0.01% 1560
2024
Q2 		$68.3K Sell
12,190
-8,333
-41% -$36.3K ﹤0.01% 1669
2024
Q1 		$108K Sell
20,523
-18,377
-47% -$101K ﹤0.01% 1782
2023
Q4 		$203K Buy
38,900
+24,600
+172% +$243K 0.01% 1552
2023
Q3 		$226K Sell
14,300
-1,100
-7% -$19.8K 0.01% 1453
2023
Q2 		$299K Sell
15,400
-10,051
-39% -$238K 0.01% 1306
2023
Q1 		$722K Buy
25,451
+18,187
+250% +$540K 0.03% 738
2022
Q4 		$212K Buy
+7,264
New +$231K 0.01% 1255
2022
Q1 		– Sell
-4,700
Closed -$239K – 1993
2021
Q4 		$239K Buy
+4,700
New +$244K 0.02% 1017
2021
Q3 		– Sell
-6,600
Closed -$282K – 1589
2021
Q2 		$282K Buy
6,600
+1,100
+20% +$45.4K 0.03% 694
2021
Q1 		$230K Buy
+5,500
New +$255K 0.02% 716

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Jump Financial's EGRX Position: Q4 2024 in Review

Jump Financial sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 10,734 shares — an estimated $40K sold.

Jump Financial first reported a position in EGRX in Q1 2021 and held it in 11 quarters. The position peaked at $722K in Q1 2023. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Jump Financial reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Jump Financial sold 10,734 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $40K.
  • Jump Financial first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2021 and held it in 11 quarters.
  • Jump Financial's Eagle Pharmaceuticals, Inc. position peaked at $722K in Q1 2023.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Jump Financial's 13F filing for Q4 2024, filed 13 Feb 2025.